SOURCE: Cavit Sciences, Inc.

April 13, 2007 08:00 ET

Cavit Sciences, Inc. Announces Plans to Have a Drug Manufactured and Apply for U.S. FDA Approval

DELRAY BEACH, FL -- (MARKET WIRE) -- April 13, 2007 --Cavit Sciences, Inc. ("Cavit") (OTCBB: CVIT) today announced its plans to have one of the drugs it tested manufactured and apply for FDA approval.

Testing performed on certain drugs has resulted in patent applications and numerous intellectual property rights which are owned and controlled by Cavit. We intend to have a third party manufacture, per U.S. FDA specifications, one of the drugs we tested, and to apply for U.S. FDA approval for certain cancer and/or viral infection indications. In addition to the current utility rights we own, Cavit will have a source and control of the drug. Due to the safety and effectiveness of the drug's use outside the U.S., Cavit will apply for fast track or priority approval by the U. S. FDA. Cavit's board has decided to focus on and to pursue the best course of action in the interest of patients and shareholders.

We have been and are currently negotiating with other drug companies regarding securing rights to their drug compositions. The combination of our current utility rights and the acquisition of composition rights should allow Cavit to develop, market and commercialize these drugs successfully.

Cavit's plant facilities in Miami are nearly completed and we will be moving in shortly. The facilities will provide ample room for the development of Cavit's food supplement line. Shareholders and investors will be kept abreast of Cavit's progress regarding drug development and our food supplement line.

Cavit Sciences, Inc. ("Cavit") is a biotechnology company engaged in developing treatments of cancer and viral infections. Additional information is available on the Company's soon to be updated website at: www.cavitsciences.com

Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are subject to a variety of risks and uncertainties. Cavit's food supplements are not intended to diagnose, treat, cure or prevent any disease; they have not been evaluated by the Food and Drug Administration and the efficacy of these products has not been confirmed by FDA-approved research. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements made by Cavit. These factors include, but are not limited to: (i) the ability of Cavit to successfully raise financing, (ii) the ability of Cavit to finalize its manufacturing and distribution facilities, and (iii) the ability of Cavit to successfully commercialize its products in certain markets. Additional factors that would cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Cavit's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" for Cavit on Form 10K-SB filed on April 12, 2007.

Contact Information